Herington A C, Kuffer A D
Biochem J. 1984 Oct 1;223(1):89-96. doi: 10.1042/bj2230089.
The biological activities of an acidic form of non-suppressible insulin-like activity (ILA pI 4.8) have been studied. ILA pI 4.8 was isolated from Cohn fraction IV-1 of human serum by pH 5.5 ion-exchange chromatography on SP-Sephadex. Carrier-bound ILA was eluted at pH 9.7 and then sequentially gel chromatographed in 1% formic acid on Sephadex G-75 and Bio-Gel P-30. The low-Mr (7000) active material was subjected to flat bed isoelectric focusing. Overall recovery was 87 munit of insulin equivalents/100 g of Cohn fraction IV-1, with a specific activity in the range 4-10 munit/mg of protein, representing a purity of 1-6%. This material has been tested in a variety of insulin-like growth factor (IGF)/somatomedin assay systems. It stimulated, in a dose-related manner, [14C]glucose conversion into lipid by isolated rat adipocytes, 35SO4(2-) incorporation into weanling rat costal cartilage and [3H]thymidine incorporation into DNA of cultured human fibroblasts. Like IGF-I and -II, ILA pI 4.8 was able to inhibit degradation of 125I-insulin by crude homogenates of rat liver. In addition, the biological activity of ILA pI 4.8 was completely suppressible by a recently described inhibitor of IGF-I and IGF-II. ILA pI 4.8 was able to compete, in a parallel manner, with 125I-IGF-I and 125I-IGF-II and, at higher doses, with 125I-insulin in a placental radioreceptor assay. No cross-reactivity was seen in a radioimmunoassay for IGF-I and -II C-peptides, but at higher concentrations parallel displacement was observed in a somatomedin C/IGF-I radioimmunoassay using two different antisera. These data indicate that ILA pI 4.8 does possess many of the biological activities previously reported for the IGFs. Since ILA pI 4.8 does occur naturally in serum, it would appear reasonable to tentatively include it as one of the IGF/somatomedin family.
对一种酸性形式的非抑制性胰岛素样活性物质(ILA pI 4.8)的生物学活性进行了研究。ILA pI 4.8通过在SP - Sephadex上进行pH 5.5离子交换色谱法从人血清的Cohn组分IV - 1中分离得到。结合载体的ILA在pH 9.7时洗脱,然后依次在1%甲酸中于Sephadex G - 75和Bio - Gel P - 30上进行凝胶色谱分离。低分子量(7000)的活性物质进行平板等电聚焦。总体回收率为87胰岛素当量单位/100 g Cohn组分IV - 1,比活性在4 - 10单位/毫克蛋白质范围内,纯度为1 - 6%。该物质已在多种胰岛素样生长因子(IGF)/生长调节素测定系统中进行了测试。它以剂量相关的方式刺激分离的大鼠脂肪细胞将[14C]葡萄糖转化为脂质、刺激断奶大鼠肋软骨摄取35SO4(2-)以及刺激培养的人成纤维细胞DNA摄取[3H]胸苷。与IGF - I和 - II一样,ILA pI 4.8能够抑制大鼠肝脏粗匀浆对125I - 胰岛素的降解。此外,ILA pI 4.8的生物学活性可被最近描述的一种IGF - I和IGF - II抑制剂完全抑制。在胎盘放射受体测定中,ILA pI 4.8能够与125I - IGF - I和125I - IGF - II以平行方式竞争,并且在较高剂量时与125I - 胰岛素竞争。在IGF - I和 - II C - 肽的放射免疫测定中未观察到交叉反应,但在使用两种不同抗血清的生长调节素C/IGF - I放射免疫测定中,在较高浓度下观察到平行位移。这些数据表明ILA pI 4.8确实具有许多先前报道的IGF的生物学活性。由于ILA pI 4.8确实天然存在于血清中,将其暂时纳入IGF/生长调节素家族似乎是合理的。